CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib
mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute